Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Pathologic Complete Response × Induction Chemotherapy × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Nasopharyngeal Carcinoma 5 Rectal Neoplasms 1 Pathologic Complete Response 1 Pancreatic Neoplasms 1 Nasopharyngeal Neoplasms 1 Lung Neoplasms 1 Locally Advanced Malignant Neoplasm 1 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasm Female 1 Anus Neoplasms 1

Interventions

Cyclophosphamide 3 Epirubicin 2 Docetaxel 2 Carboplatin 2 Capecitabine 2 Azacitidine 2 venetoclax 1 tegafur-gimeracil-oteracil 1 taxane 1 sargramostim 1 ruxolitinib 1 rucaparib 1 pirarubicin 1 pertuzumab 1 pembrolizumab 1 olaparib 1 cc-486 1 Trastuzumab 1 Thalidomide 1 Radiotherapy 1 Radiation 1 Platinum 1 Paclitaxel 1 Oxaliplatin 1 Observation 1 Nivolumab 1 Monatide (IMS 3015) 1 Methotrexate 1 Magnetic Resonance Imaging 1 Leucovorin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07472868 2026-03-16

MEND-IT II

Catharina Ziekenhuis Eindhoven

Phase 3 Not yet recruiting

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon ⚡